Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HER-2 S310F

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

HER-2 S310F	Solid Tumor	HER-2 S310F	Solid Tumor	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2
HER-2 S310F	Breast Cancer	HER-2 S310F	Breast Cancer	trastuzumab + everolimus Sensitive: C3 – Early Trials trastuzumab + everolimus Sensitive : C3	trastuzumab + everolimus Sensitive: C3 – Early Trials trastuzumab + everolimus Sensitive : C3
HER-2 S310F	HER2 Negative Breast Cancer	HER-2 S310F	HER2 Negative Breast Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 S310F	Lung Adenocarcinoma	HER-2 S310F	Lung Adenocarcinoma	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4
HER-2 S310F	Colorectal Cancer	HER-2 S310F	Colorectal Cancer	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4
HER-2 S310F	HER2 Negative Breast Cancer	HER-2 S310F	HER2 Negative Breast Cancer	lapatinib Sensitive: C4 – Case Studies lapatinib Sensitive : C4	lapatinib Sensitive: C4 – Case Studies lapatinib Sensitive : C4
HER-2 S310F	Gallbladder Cancer	HER-2 S310F	Gallbladder Cancer	lapatinib Sensitive: C4 – Case Studies lapatinib Sensitive : C4	lapatinib Sensitive: C4 – Case Studies lapatinib Sensitive : C4
HER-2 S310F	Non Small Cell Lung Cancer	HER-2 S310F	Non Small Cell Lung Cancer	ado-trastuzumab emtansine Sensitive: D – Preclinical ado-trastuzumab emtansine Sensitive : D	ado-trastuzumab emtansine Sensitive: D – Preclinical ado-trastuzumab emtansine Sensitive : D
HER-2 S310F	Colorectal Cancer	HER-2 S310F	Colorectal Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D
HER-2 S310F	Colorectal Cancer	HER-2 S310F	Colorectal Cancer	panitumumab Resistant: D – Preclinical panitumumab Resistant : D	panitumumab Resistant: D – Preclinical panitumumab Resistant : D